Bioqore Advances Biomanufacturing in Drug Development with Predictive AI & Appoints Janette Phi to Lead Business Growth

The appointment follows advances in its AI-driven platform and deployment to active clinical-stage therapeutic programs, supporting broader industry adoption.

NATICK, MA, UNITED STATES, November 12, 2026 /EINPresswire.com/ -- Bioqore Technologies, Inc. today announced the appointment of life sciences veteran Janette Phi as Chief Business Officer to lead commercialization of its predictive AI solution to address critical manufacturing challenges in drug development. The appointment follows significant advances in Bioqore's proprietary Voyager platform, which combines predictive AI with automated wet lab validation to accelerate and derisk bioprocess development. With its technology applied across several active therapeutic development programs, Bioqore is strengthening its commercial leadership to expand industry adoption and drive its next phase of growth.

Advances in AI have ushered in a new era of drug discovery, accelerating the identification and design of promising new therapeutics. Yet the infrastructure needed to manufacture these innovations has not kept pace. Traditional bioprocess development remains slow, costly, and unpredictable, creating a critical bottleneck between scientific discovery and clinical development. Dr. Josh Hinckley, with multidisciplinary expertise spanning bioengineering and cancer immunology, founded Bioqore to fundamentally change that process.

Bioqore's Voyager platform integrates proprietary Bayesian AI with automated wet-lab experimentation utilizing continuous bioprocess optimization for increased success rates while significantly reducing time and cost of manufacturing. Unlike software-only approaches, Voyager integrates predictive modeling with experimental validation, enabling more informed decision-making while continuously expanding its foundation of validated process data. The technology has advanced beyond initial proof-of-concept validation and is being applied to active therapeutic development programs at the clinical stage.

"We believe the next major advance in drug development isn't just about discovering better therapeutics—it's about fundamentally improving how we manufacture them," said Josh Hinckley, Founder and CEO of Bioqore. "We've built a technology foundation that brings predictive intelligence together with experimental proof. Now we're focused on expanding its impact."

Newly appointed Chief Business Officer, Janette Phi, brings more than three decades of business and commercialization leadership experience across the life sciences industry, including roles at Deepcell, ThinkCyte, IntelliCyt, and ForteBio. As CBO, she will lead Bioqore's commercial strategy and industry partnerships, helping translate the capabilities of its Voyager platform into broader opportunities across biotechnology and pharmaceutical development.

With an established technical foundation and experienced commercial leadership, Bioqore is positioned to accelerate its transition from technology development to broader industry adoption. The company will focus on expanding collaborations with drug developers, addressing critical challenges in biologics process development and manufacturing readiness, and building strategic partnerships that bring its predictive AI technology into more therapeutic development programs.

About Bioqore Technologies

Bioqore Technologies is developing predictive AI-driven solutions for biologics process development and manufacturing readiness. Its proprietary Voyager platform combines Bayesian optimization with automated wet-lab validation to reduce experimental uncertainty and help drug developers advance toward more efficient, scalable manufacturing processes.

Learn more at bioqore.ai.

Nick Wilson
Kaironexus Innovations
nick@kaironexus.bio
Visit us on social media:
LinkedIn